NCT07169383 (Melasma) is a Phase 2 clinical trial of Melatonin tablet in Melasma (Facial Melasma), sponsored by Hina Malik.

Who is sponsoring NCT07169383?

NCT07169383 is sponsored by Hina Malik.

What drugs are being tested in NCT07169383?

Interventions in NCT07169383: Melatonin tablet, Tranexamic Acid (TXA).

What condition does NCT07169383 study?

NCT07169383 studies Melasma (Facial Melasma).

Is NCT07169383 still recruiting?

NCT07169383 is currently enrolling by invitation. Last updated 11 September 2025.

Last reviewed 2025-09-11 · How we verify

NCT07169383: Melasma

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oral Melatonin Versus Oral Tranexamic Acid in the Management of Melasma

ENROLLING BY INVITATION Phase 2 Last updated 11 September 2025

What this trial tests

Phase 2 trial testing Melatonin tablet in Melasma (Facial Melasma) in 160 participants. Enrolling by invitation.

Timeline

28 June 2025

Primary endpoint
28 December 2025

28 December 2025

Quick facts

Lead sponsor	Hina Malik
Phase	Phase 2
Status	ENROLLING BY INVITATION
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	160
Start date	28 June 2025
Primary completion	28 December 2025
Estimated completion	28 December 2025
Sites	1 location across Pakistan

Drugs / interventions tested

Melatonin tablet
Tranexamic Acid (TXA) — full drug profile →

Conditions studied

Melasma (Facial Melasma) — all drugs for Melasma (Facial Melasma) →

Sponsor

Hina Malik

Who can join

Adults 18 to 50, any sex, with Melasma (Facial Melasma). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will compare the efficacy of oral melatonin and oral tranexamic acid in treating melasma, with the aim of determining whether melatonin is more effective than tranexamic acid, as measured by MASI scores. Literature suggests melatonin may be more effective due to its antioxidant, anti-inflammatory, and anti-melanogenic properties. The findings will assess whether melatonin provides better efficacy and tolerance compared to tranexamic acid in managing this persistent condition. Efficacy will be assessed by comparing the baseline MASI scores with the scores obtained at six-week and twelve-week follow-up points based on the following cut-offs: \<25% improvement Mild response 25-50% improvement Moderate Response 51-75% improvement Good response \>75% improvement Excellent Response

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Melasma (Facial Melasma)

Currently open trials in the same condition.

NCT07071363 — COMPARISON OF A COSMETIC SERUM AND 4% HYDROQUINONE FOR TREATING MELASMA OVER 84 DAYS · NA · recruiting
NCT07202156 — Ultrasound-Enhanced Delivery of Compound TXA Solution in Melasma · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07169383 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hina Malik
Last refreshed: 11 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07169383.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing